Success Metrics

Clinical Success Rate
93.0%

Based on 40 completed trials

Completion Rate
93%(40/43)
Active Trials
8(13%)
Results Posted
40%(16 trials)
Terminated
3(5%)

Phase Distribution

Ph phase_2
13
20%
Ph phase_4
8
13%
Ph early_phase_1
1
2%
Ph phase_1
23
36%
Ph not_applicable
17
27%
Ph phase_3
1
2%

Phase Distribution

24

Early Stage

13

Mid Stage

9

Late Stage

Phase Distribution63 total trials
Early Phase 1First-in-human
1(1.6%)
Phase 1Safety & dosage
23(36.5%)
Phase 2Efficacy & side effects
13(20.6%)
Phase 3Large-scale testing
1(1.6%)
Phase 4Post-market surveillance
8(12.7%)
N/ANon-phased studies
17(27.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

40 of 48 finished

Non-Completion Rate

16.7%

8 ended early

Currently Active

8

trials recruiting

Total Trials

64

all time

Status Distribution
Active(11)
Completed(40)
Terminated(8)
Other(5)

Detailed Status

Completed40
unknown5
Withdrawn5
Active, not recruiting5
Recruiting3
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
64
Active
8
Success Rate
93.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.6%)
Phase 123 (36.5%)
Phase 213 (20.6%)
Phase 31 (1.6%)
Phase 48 (12.7%)
N/A17 (27.0%)

Trials by Status

unknown58%
withdrawn58%
completed4063%
recruiting35%
terminated35%
not_yet_recruiting35%
active_not_recruiting58%

Recent Activity

Clinical Trials (64)

Showing 20 of 64 trialsScroll for more
NCT06424106Not Applicable

Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes

Recruiting
NCT02817659Phase 1

To Determine Tolerability to Glucagon Infusion in Obese Subjects

Active Not Recruiting
NCT03139305Phase 1

Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects

Active Not Recruiting
NCT06252493

Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.

Recruiting
NCT06558422Phase 1

Human Models of Selective Insulin Resistance: Pancreatic Clamp

Not Yet Recruiting
NCT07366710Not Applicable

Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET

Active Not Recruiting
NCT05724134Phase 1

Pancreatic Clamp in NAFLD

Completed
NCT06921824Not Applicable

Investigating the Acute Effects of Increasing Glucagon Exposure in Healthy Participants

Completed
NCT07300982Phase 1

Studies of Insulin and Glucagon Action in the Liver

Not Yet Recruiting
NCT06588504Phase 1

Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents

Completed
NCT06872060Not Applicable

The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance.

Not Yet Recruiting
NCT03241706Phase 1

Liver Glycogen and Hypoglycemia in Humans

Active Not Recruiting
NCT02078726Phase 4

Glucagon Use in Colonoscopies

Completed
NCT05960565Phase 2

Glucagon Enhanced Insulin Absorption in Diabetes Mellitus Type 1

Terminated
NCT03965130Phase 1

The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA

Completed
NCT06498063Not Applicable

The Underlying Mechanisms Regarding the Effect of Glucagon on the Kidneys Will be Investigated in Healthy Males.

Recruiting
NCT06126354Phase 1

Dexamethasone/Pancreatic Clamp P&F

Withdrawn
NCT04859322Not Applicable

The Effect of Lifestyle-induced Hepatic Steatosis on Glucagon-stimulated Amino Acid Turnover

Completed
NCT05095259Not Applicable

Metabolic Adaptation to High-frequent Hypoglycaemia in Type 1 Diabetes

Unknown
NCT04042142Not Applicable

Glucagon Resistance in Patients With NAFLD

Completed

Drug Details

Intervention Type
OTHER
Total Trials
64